MedPath

CORIXA CORPORATION

🇺🇸United States
Ownership
-
Employees
-
Market Cap
-
Website

Clinical Trials

8

Active:0
Completed:1

Trial Phases

4 Phases

Phase 1:3
Phase 2:2
Phase 3:1
+1 more phases

Drug Approvals

2

CANADA:1

Drug Approvals

MELACINE

Approval Date
Jan 25, 2001
CANADA

Clinical Trials

Distribution across different clinical trial phases (8 trials with phase data)• Click on a phase to view related trials

Phase 1
3 (37.5%)
Not Applicable
2 (25.0%)
Phase 2
2 (25.0%)
Phase 3
1 (12.5%)

A Study of Rituximab Versus Iodine I 131 Tositumomab Therapy for Patients With Non-Hodgkin's Lymphoma

Phase 3
Conditions
Non-Hodgkin's Lymphoma
First Posted Date
2004-03-03
Last Posted Date
2005-11-09
Lead Sponsor
Corixa Corporation
Target Recruit Count
506
Registration Number
NCT00078598
Locations
🇺🇸

Northside Hospital, Atlanta, Georgia, United States

🇺🇸

Medical Oncology/Hematology Associates, Dayton, Ohio, United States

🇺🇸

Madigan Army Medical Center, Tacoma, Washington, United States

and more 2 locations

Safety and Immunogenicity of Recombinant DNA and Adenovirus Expressing L523S Protein in Early Stage Non-Small Cell Lung Cancer

Phase 1
Conditions
Non-Small Cell Lung Cancer
First Posted Date
2003-06-19
Last Posted Date
2006-12-06
Lead Sponsor
Corixa Corporation
Target Recruit Count
9
Registration Number
NCT00062907
Locations
🇺🇸

Cancer Centers of Florida, Ocoee, Florida, United States

🇺🇸

Mary Crowley Medical Research Clinic, Dallas, Texas, United States

🇺🇸

Tyler Cancer Center, Tyler, Texas, United States

and more 2 locations

Expanded Access Study of Iodine-131 Anti-B1 Antibody

Not Applicable
Conditions
Non-Hodgkin's Lymphoma
First Posted Date
2001-08-20
Last Posted Date
2005-06-24
Lead Sponsor
Corixa Corporation
Registration Number
NCT00022958
Locations
🇺🇸

Central Recruiting Information, South San Francisco, California, United States

Safety and Efficacy of Iodine-131 Anti-B1 Antibody for Intermediate Grade Non-Hodgkin's Lymphoma Following First Line CHOP

Phase 2
Conditions
Non-Hodgkin's Lymphoma
First Posted Date
2001-08-20
Last Posted Date
2005-06-24
Lead Sponsor
Corixa Corporation
Registration Number
NCT00022932
Locations
🇺🇸

Rush Medical Center, Chicago, Illinois, United States

🇺🇸

Tufts New England Medical Center, Boston, Massachusetts, United States

🇺🇸

Cornell Medical Center, New York, New York, United States

Safety and Efficacy Study of Iodine-131 Anti-B1 Antibody Plus CHOP For Untreated Mantle Cell Lymphoma

Phase 2
Completed
Conditions
Mantle Cell Lymphoma
First Posted Date
2001-08-20
Last Posted Date
2005-06-24
Lead Sponsor
Corixa Corporation
Registration Number
NCT00022945
Locations
🇺🇸

Rush-Presbyterian-St. Lukes Medical Center, Chicago, Illinois, United States

🇺🇸

Memorial Sloan-Kettering Cancer Center, New York, New York, United States

🇺🇸

Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States

  • Prev
  • 1
  • 2
  • Next

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.